1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...
1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ... 1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...
Editorial Advisory Board:Reviews on Recent Clinical TrialsClinical Cancer Research (American Association for Cancer Research)Study section peer review activitiesDateActivity2009 Reviewer, NIH ZRG1 BDA-A (52) study section2009 Reviewer, Terry Fox New Frontiers Program in Cancer2012 External Peer Reviewer, British Lung Foundation2012 External Peer Reviewer, Swiss Cancer LeagueOther consultant activities or positionsDateActivity2009-2011 Member, Junior Investigator Task Force, American Society of Gene and CellTherapy (ASGCT)2010-presentMember, Cancer Gene and Cell Therapy Committee, American Society ofGene and Cell Therapy (ASGCT)2010-2012 Member, Website Task Force, American Society of Gene and Cell Therapy(ASGCT)2011-presentMember, Scientific Program Committee, American Society of ClinicalOncology (ASCO)5/17/10 - 5/22/10 Abstract Reviewer, American Society of Gene and Cell Therapy (ASGCT)Annual Meeting: “Immunologic and Host Responses in Gene and Cell Therapy”Track, ASGCT 13 th Annual Meeting, Washington DC6/1/12 - 6/5/12 Abstract Reviewer, American Society of Clinical Oncology (ASCO) AnnualMeeting: “Developmental Therapeutics – Clinical Pharmacology andImmunotherapy” Track, ASCO 48 th Annual Meeting, Chicago, IL5/15/13 - 5/18/13 Abstract Reviewer, American Society of Gene and Cell Therapy (ASGCT)Annual Meeting: “Immunologic and Host Responses in Gene and Cell Therapy”Track, ASGCT 16 th Annual Meeting, Salt Lake City, Utah14
L. BIBLIOGRAPHY1. Brentjens RJ, Spinola SM, Campagnari AA. Haemophilus ducreyi adheres to keratinocytes. MicrobialPathogen. 16:263-267, 1994. PMID: 80900822. Brentjens RJ, Ketterer M, Apicella MA, Spinola SM. Fine tangled pili expressed by Haemophilus ducreyiare a novel class of pili. J. Bact. 178:808-816, 1996. PMID: 85505173. Brentjens RJ, Smith L, Reich L, Jakubowski AA. Development of spontaneous factor VIII inhibitor inassociation with acute graft versus host disease. Bone Marrow Trans. 27:887-889, 2001. PMID: 114774494. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T lymphocyte cytotoxicity and proliferationdirected by a single chimeric TCRζ/CD28 receptor. Nat. Biotech. 20:70-75, 2002. PMID: 117533655. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, RiviereI, Sadelain M. Eradication of systemic B cell tumors by genetically targeted human T lymphocytes costimulatedby CD80 and interleukin-15. Nat. Med. 9:279-286, 2003. PMID: 125791966. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M,Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Riviere I, Larson SM, Koutcher JA,Sadelain M. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. CancerRes. 65(19):9080-8, 2005. PMID: 162040837. Lammana N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz AD, Horgan D, GencarelliA, Panageas KS, Scheinberg DA, Weiss MA. Pentostatin, cyclophosphamide, and rituximab is an active,well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol.24(10):1575-81, 2006. PMID: 165204648. McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, BrentjensR, Scheinberg DA. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nuc Med48(7):1180-9, 2007. PMID: 176070409. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintas-Cardama A, Larson S,Sadelain M. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts bygenetically targeted T cells. Clin Can Res 13(18): 5426-35, 2007. PMID: 1785564910. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell encodedCD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 13(12):1440-9, 2007. PMID: 1802611511. Quintas-Cardama A, Yeh RK, Hollyman D, Stefanski J, Nikhamin Y, Imperato G, Sadelain M, Riviere I,Brentjens RJ. Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes forclinical application. Hum Gen Ther 18(12): 1253-60, 2007. PMID: 1805271912. Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg JM, Jenk R, Holland AM, Gurbin J,Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant-Angelo DB, Riviere I, Sadelain M, Heller G, Zuniga-Pflucker JC, Lu C, van den Brink MR. Tumor immunotherapy across MHC barriers using allogeneic T cellprecursors. Nat Biotech 26 (4):453-61, 2008. PMID: 1837639915
- Page 1 and 2: Memorial Sloan-Kettering Cancer Cen
- Page 3 and 4: 3. Hospital positions (e.g., attend
- Page 5 and 6: Kendrick Kelly History Scholar 1988
- Page 7 and 8: Sarwish Rafiq PhD; Role: Post Doc F
- Page 9 and 10: Experimental Therapeutics Center Pr
- Page 11 and 12: 3/29/2009 “Adoptive T cell therap
- Page 13: 10/19/2012 “Chimeric antigen rece
- Page 17 and 18: 1. Books, book chapters and reviews
- Page 19 and 20: 11. R. Brentjens, E. Santos, R. Yeh
- Page 21 and 22: 35. M.L. Davila, C.Taylor, X.Wang,
- Page 23: 56. E. Halton, D. Chung, K. Xiao, H
Editorial Advisory Board:Reviews on Recent Clinical TrialsClinical <strong>Cancer</strong> Research (American Association for <strong>Cancer</strong> Research)Study section peer review activitiesDateActivity2009 Reviewer, NIH ZRG1 BDA-A (52) study section2009 Reviewer, Terry Fox New Frontiers Program in <strong>Cancer</strong>2012 External Peer Reviewer, British Lung Foundation2012 External Peer Reviewer, Swiss <strong>Cancer</strong> LeagueOther consultant activities or positionsDateActivity2009-2011 Member, Junior Investigator Task Force, American Society of Gene <strong>and</strong> CellTherapy (ASGCT)2010-presentMember, <strong>Cancer</strong> Gene <strong>and</strong> Cell Therapy Committee, American Society ofGene <strong>and</strong> Cell Therapy (ASGCT)2010-2012 Member, Website Task Force, American Society of Gene <strong>and</strong> Cell Therapy(ASGCT)2011-presentMember, Scientific Program Committee, American Society of ClinicalOncology (ASCO)5/17/10 - 5/22/10 Abstract Reviewer, American Society of Gene <strong>and</strong> Cell Therapy (ASGCT)Annual Meeting: “Immunologic <strong>and</strong> Host Responses in Gene <strong>and</strong> Cell Therapy”Track, ASGCT 13 th Annual Meeting, Washington DC6/1/12 - 6/5/12 Abstract Reviewer, American Society of Clinical Oncology (ASCO) AnnualMeeting: “Developmental Therapeutics – Clinical Pharmacology <strong>and</strong>Immunotherapy” Track, ASCO 48 th Annual Meeting, Chicago, IL5/15/13 - 5/18/13 Abstract Reviewer, American Society of Gene <strong>and</strong> Cell Therapy (ASGCT)Annual Meeting: “Immunologic <strong>and</strong> Host Responses in Gene <strong>and</strong> Cell Therapy”Track, ASGCT 16 th Annual Meeting, Salt Lake City, Utah14
Change language